The public commentary period for the next round of Pharmaceutical Benefits Advisory Committee (PBAC) considerations is now open.
MS treatment Fampyra -produced by Biogen Idec - is being considered for subsidisation by the Federal Government through the PBAC this March.
Fampyra (fampridine) is designed to help increase the mobility in people with MS. It has proven in clinical trials to be effective in adult patients with MS who have a walking disability. Walking impairment is a common symptom of MS, which greatly affects independence and quality of life.
As is always the case with these deliberations, comments and feedback from patients, carers, members of the public, healthcare professionals and patient advocacy groups, who have knowledge of the treatment, are welcomed as part of this process.
If you would like to comment you can submit feedback online (preferable) or via hard-copy. The online submission form can be accessed using the following link:
More information on the submission process, including the March 2014 PBAC meeting agenda, will be available from the following link: